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SUMMARY  
Background: Metronomic chemotherapy (MCT) refers to the chronic and equally spaced 
administration of low doses of different chemotherapy drugs, without extended rest periods. 
Herein we investigated the therapeutic efficacy of metronomic cyclophosphamide (Cy) 
combined with doxorubicin (Dox) in two mouse mammary adenocarcinoma models. 
Materials and methods: Mice were s.c. challenged with M-234p or M-406 mammary 
tumors and when the tumors reached approximately 150 mm3 they were treated with: I) No 
treatment (controls); II) Cy in the drinking water (30 mg/kg body weight/day); III) Dox (0.5 
mg/kg body weight i.p. three times/week); IV) Treated as II + III. Mice challenged i.v. with 
M-234p or M-406 tumor cells received, on day 3, the same treatments. Results: We found 
that MCT with Cy plus Dox inhibited tumor growth, decreased lung metastases, and 
increased the median survival time, while having low toxicity. Combined MCT was more 
effective than each monotherapy causing decrease in VEGF serum concentration and tumor 
proliferation rate plus increase in tumor apoptosis. Conclusions: The therapeutic benefits of 
combined MCT with Cy and Dox on mammary adenocarcinomas together with its low 
toxicity profile suggest the possibility of future translation into the clinic.  
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INTRODUCTION 
Metronomic chemotherapy (MCT) involves the chronic administration of doses of 
chemotherapy drugs that are below the maximum tolerated dose (MTD), at frequent and 
regular intervals, without extended rest periods [1]. It aims to achieve a balance between 
efficacy in tumor killing and lack of toxicity. The inhibition of angiogenesis would explain 
its therapeutic effect [2, 3].  
We have demonstrated the antitumor efficacy of MCT with cyclophosphamide (Cy) as a 
single drug [4] and in combination with celecoxib on mice mammary adenocarcinomas 
(MA) [5]. Considering the high incidence of mammary tumors in humans, in this study, we 
analyze the therapeutic efficacy, toxicity and mechanism/s of action of MCT combining Cy 
and doxorubicin (Dox), in mouse MA tumor-models. 
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MATERIALS AND METHODS 
Animals 
Inbred BALB/c and CBi [6] female mice were obtained from our breeding facilities. 
Animals were fed with commercial chow and water ad libitum and maintained in a 12 h 
light/dark cycle and were treated in accordance to the Canadian Council on Animal Care 
guidelines. Tumor bearing mice were euthanized by CO2 exposure.  
Drugs 
Cyclophosphamide: It was dissolved in sterile distilled water at a concentration of 
20mg/mL and diluted in the drinking water to reach 0.12 mg/mL. Drinking water was 
replaced every other day and the mice's daily Cy intake/kg body weight (BW) was 
calculated.  
Doxorubicin: It was dissolved in sterile saline immediately before its intraperitoneal 
injection. 
Tumors 
M-234p: It is a moderately differentiated type ‘B’ MA [7]. It spontaneously arose in a 
BALB/c female mouse and it is maintained in vivo by serial subcutaneous passages in 
syngeneic mice, with 100% of incidence.  
M-406: It is a type ‘B’ MA, which appeared spontaneously in an inbred CBi female mouse. 
It is maintained in vivo by serial intraperitoneal passages in syngeneic mice, with 100% of 
incidence.  
Experimental models 
Antitumor effect: Adult BALB/c or CBi mice were implanted s.c. with 1 mm3 M-234p or 
M-406 tumor fragments, respectively. Five (M-234p) or eight (M-406) days later, when 
tumors reached 150 mm3, animals (N=5-8/group) were distributed and treated as follows: 
Control: no treatment; Cy: in drinking water (30 mg/kg BW/day); Dox: 0.5 mg/kg BW, 
i.p., three times/week; Cy+Dox: Cy and Dox treatments combined. Tumors were measured 
and tumor volumes calculated Animals were weighed twice/week, and blood samples were 
obtained on day 0 and days 24 (M-234p) or 25 (M-406) for white blood cell count, Tregs 
and VEGF determinations. When the first animal reached the largest ethically permitted 
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tumor volume (LPV), animals belonging to the four groups were euthanized and tumors 
were excised and processed for histology and immunohistochemistry, as described below. 
For survival studies, in a duplicate experiment, animals were euthanized when each one 
reached LPV. 
Antimetastatic effect: Adult BALB/c and CBi mice were injected intravenously with 5x105 
M-234p cells or 2x105 M-406 cells in 0.1mL saline. On day 3, animals (M-234p: N=7-
8/group; M-406: 5-6/group) were treated as indicated above. The animals were controlled 
daily and weighed twice/week. All the mice were euthanized by the time the first mouse 
showed signs of metastatic illness. Lungs were excised, weighed and fixed and the number 
and size of metastatic foci determined. The effect of the different treatments on survival 
was assessed in a duplicate experiment in which each animal was sacrificed when it showed 
signs of metastatic illness.  
VEGF serum concentration 
Serum VEGF was quantified with Quantikine© ELISA kit (R & D Systems Inc, 
Minneapolis, U.S.A) and performed in duplicates. 
Histological and Immunohistochemical Studies 
Tumors were excised on days 31 (M-234p) and 26 (M-406), fixed in 10% buffered 
formalin and paraffin-embedded. Five μm thickness sections were used for 
immunohistochemical studies or stained with hematoxylin-eosin.  
Tumor microvascular density (MVD) and area (MVA): They were determined using 
immunostaining for CD31 endothelial marker (eBioscience). The number of CD31+ blood 
vessels/field was calculated in three hot spots areas at 400X. For MVA (vessel wall+lumen 
area) quantification ImageJ program (U. S. NIH, Bethesda, Maryland, USA) was utilized.  
Ki67 proliferation marker: Tumor sections were incubated with anti-Ki-67 antibody 
(Abcam, Cambridge, MA USA). The percentage of Ki67+ cells was determined in 30 fields 
(1000X) utilizing the following score: 0=0%, 2<20%, 4=20-40%, 6=40-60%, 8>60%.   
Apoptosis: Tumor sections were immunostained by the TUNEL method (ApopTag® In Situ 
Apoptosis Detection Kit, Millipore, MA). Apoptotic cells were counted in 30 fields 
(1000X). 
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Treg cells quantification  
Circulating natural Treg cells (CD4+CD25+Foxp3+) were determined by flow cytometry 
using the Mouse regulatory T cell staining kit (eBioscience, San Diego CA, USA). Cells 
were analyzed in a Coulter Epics XL (Coulter Corp. Miami, FL, USA) cytometer. Acquired 
data were analyzed with WinMD1 2.8 data analysis software (Scripps Research Institute, 
La Jolla, Ca, USA). 
Statistical analysis 
ANOVA and Tukey-Kramer Multiple Comparison tests, Kruskal-Wallis and Dunn's post-
test, and Log-rank test were used to examine the differences between groups with 
GraphPad Prism version 3.0 (GraphPad Software, San Diego, CA). Differences were 
considered statistically significant at P<0.05.  
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RESULTS 
Antitumor effect 
Tumor growth inhibition 
M-234p in Cy and Cy+Dox groups showed smaller volumes than that in Control group 
(P<0.05) on day 28, just before almost all the animals in this group were sacrificed 
(Fig.1A). Tumor volume in Cy+Dox group varied from lower to higher values than those of 
the Cy group, ending (day 68) with a volume significantly smaller than that in Cy group.  
M-406 showed that tumor volume in Cy or Cy+Dox groups were, on day 23, lower 
(P<0.01) compared to Control and Dox groups (Fig. 1B). On day 50 the tumor volume in 
Cy+Dox group was significantly lower than that observed in the Cy group (P<0.05). 
Interestingly, 1/6 animals in Cy+Dox group showed a complete tumor regression which, 
despite of the withdrawal of treatment, lasted until the end of the experiment (day 120). 
Survival 
M234-p and M-406 bearing mice that received MCT with Cy+Dox showed a longest 
survival rate (P<0.05, P<0.01, respectively) (Fig.1C).  
In the M-406 tumor-model (day 54) all the animals in Cy+Dox group were alive, while 
100% of those belonging to Dox, Control and Cy groups were dead on days 35, 37 and 54, 
respectively (Fig. 1D). 
Antimetastatic effect 
Metastasis inhibition 
M-234p showed fewer lung metastatic foci in Cy (P<0.001) or Cy+Dox (P<0.05) than in 
Control group (Fig. 2A). M-406 developed less metastasis in Cy+Dox than in Control 
group (P<0.05) (Fig. 2B).  
The metastasis diameter in M-234p challenged animals in Cy+Dox group was lower than 
Control (P<0.001) and Cy and Dox (P<0.01) groups (Fig. 2C). In the M-406 tumor-model 
all the treated groups showed lower values, although non-statistically different, than in 
Control (Fig. 2D). The total metastatic burden for the three treated groups was significantly 
lower than in Control group in both tumor-models (Fig. 2E and 2F). 
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Survival 
Animals in Cy+Dox groups lived longer than those in the other groups for both tumors 
(P<0.0001) (Fig. 2G and 2H).  
Evaluation of toxicity 
Treated animals, monitored for their motor activity, fur quality, food intake, response to 
stimuli and breathing, showed normal characteristics throughout the experiment and did not 
experience weight loss in any of the tumor-models (Supplementary Material, S.1A and 
S.1B).  
No decrease in white blood cells counts was found in either experimental group (S.1C and 
S.1D). The experimental metastasis assays showed a similar lack of toxicity. 
VEGF serum concentration 
VEGF serum concentration in animals bearing. M-234p tumors, which had received either 
monotherapy or the combined treatment, were lower than those in Control group on day 24 
(P<0.001) (Fig. 4A). In M-406 bearing animals, those belonging to Dox and Cy+Dox 
groups showed, on day 25, lower values than in Controls (P<0.05) (Fig. 4B). 
Histological and Immunohistochemical Studies 
Tumor microvascular density and area 
MVD and MVA were determined in tumors of animals belonging to groups that showed 
the highest (Control) and lowest (Cy+Dox) VEGF levels without showing statistical 
differences for either parameter (S.2). 
Ki67 expression  
In M-234p tumor-model all the treatments diminished Ki67 tumor expression, although 
only Cy+Dox differed from Control group (P<0.05) (Fig. 4A). Cy+Dox group showed the 
lowest values in M-406 tumors, though they did not differ from the other groups (Fig. 4B). 
Photomicrographs of M-234p and M-406 tumors in Control and Cy+Dox groups are 
shown. 
Apoptosis  
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In both tumor-models the Cy+Dox group showed higher number of TUNEL+ cells than the 
Control group (Fig. 4C and 4D). For M-406 tumors, that difference reached statistical 
significance (P<0.05). Photomicrographs of M-234p and M-406 tumors in Control and 
Cy+Dox groups are shown. 
Treg cells quantification 
The percentage of circulating CD4+CD25+Foxp3+ Treg cells in treated groups did not show 
differences with respect to Control group in M-234p (day 24) (S.3A) and M-406 (day 25) 
(S.3B) tumor-models. 
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DISCUSSION 
The importance of metronomic scheduling in cancer therapeutics accounts for the 
increasing number of clinical protocols utilizing MCT in the past few years [8]. Cy and 
Dox are frequently used for the treatment of breast cancer, as monotherapies or in 
combination with other drugs [9]. Generally, the good results obtained are transitory and 
they usually have mild to severe toxicities. The possibility of obtaining similar therapeutic 
results, but avoiding toxicity through the administration of metronomic combination of 
Cy+Dox prompted us to develop pre-clinical studies in two MA tumor-models. The 
experimental models were designed in order to mimic the clinical situation of a cancer 
patient who starts adjuvant chemotherapy. Our results using MCT showed that the 
combined treatment, in both tumor-models, was most efficient in tumor growth inhibition, 
resulting in a significant increase in the overall survival. 
 
As far as we know, this is the first time that MCT with combined Cy and Dox is utilized as 
an intervention therapeutic strategy for MA, both at the experimental and clinical level. 
Shiraga found an antimetastatic effect of MCT of Cy plus low-dose liposomal Dox [10] for 
a lung tumor. Also, the activity and toxicity of MCT with Cy or Dox was studied in a rat 
breast cancer model, but the drugs were administered as monotherapies [11]. In the clinical 
field, patients with locally advanced breast cancer were treated before surgery with 
pegylated liposomal Dox combined with metronomic Cy, achieving limited therapeutic 
activity [12]. 
The development of metastasis is an important hurdle for a successful cancer treatment. 
Interestingly, the antimetastatic activity of the treatment was evidenced by a reduction in 
the number and diameter of lung metastatic nodules, although this was not significant for 
M-406, hence leading to a significant decrease in the lung metastatic burden. The groups 
Cy+Dox and Cy did not differ in some of the evaluated parameters; nevertheless, when the 
overall survival was calculated the group with combined treatment was the one that lived 
longer, with a survival rate significantly higher than that of all the other groups, including 
Cy. This data would indicate that the combined treatment may interfere with the seeding 
capacity of both tumor cell types and with metastatic growth, at least for M-234p cells. 
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These results agree with those obtained by our lab, administering MCT with Cy+Celecoxib 
[5] or by other, utilizing different tumor-models and/or other drug combinations. Cruz-
Munoz obtained a reduction of human melanoma metastasis with metronomic topotecan 
[13], while MCT with gemcitabine and sunitinib inhibited metastasis in pancreatic cancer 
[14]. In the clinical setting, advanced breast cancer patients received diverse metronomic 
treatments, showing transitory inhibition of progression [15, 16].  
The treatment showed low/null toxicity. No weight losses were detected throughout the 
experiment in any of the groups of both tumor-models. Also, no alterations were found in 
the markers of morbidity/toxicity monitored. The possibility that a chronic administration 
of Dox could induce cardiac toxicity cannot be ruled out when translating to the clinic, 
though such event has not yet been reported.  
Although MCT modulate the serum concentration of pro-angiogenic molecules, such as 
VEGF [3, 17, 18] and anti-angiogenic factors, such as TSP-1 [19], these effects do not 
always correlate with changes in the intratumoral MVD [20]. In both tumor-models, VEGF 
concentration was significantly lower in tumor-bearing mice treated with Cy+Dox than in 
Control mice. It still remains uncertain whether the reduction in VEGF levels observed in 
the Cy+Dox group is a sign of an antiangiogenic effect, or whether it is partially a 
consequence of the reduced tumor volumes. Moreover, those reductions in VEGF do not 
correlate with a concomitant diminution in MVD and MVA. Additional experimental 
research should be done to address the possibility that normalization, instead of reduction, 
of the MVD could be occurring [20] .  
The evaluation of tumor proliferation and apoptosis showed a decrease in proliferating 
cells, mainly in M-234p cells and an increase in apoptotic cells, mainly in M-406 cells. 
We demonstrated that a single-low dose of Cy downregulates the percentage of circulating 
natural and inducible Treg cells of tumor bearers [21], while, in the metronomic setting that 
was not the case. No changes with respect to controls were observed in circulating Tregs 
measured in the treated groups of both tumor-models. Some authors found that MCT 
induced a decrease of Tregs [22], while others reported the opposite[23]. So, the 
controversy is still ongoing. Nevertheless, concerning the involvement of the immune 
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response in the therapeutic effect of MCT with Cy, as demonstrated in a rat lymphoma 
model [24], the  possibility exists that the immune system would be involved in the 
antitumor effect obtained through mechanisms to be determined. 
In brief, the antitumor and antimetastatic benefits of combined MCT with Cy and Dox on 
MA together with its low toxicity profile was shown. The decrease of VEGF concentration 
and tumor cell proliferation together with the increase of tumor cell apoptosis would be 
responsible, at least in part, for the therapeutic effect achieved.  
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LEGENDS TO FIGURES 
Figure 1: Tumor growth and overall survival: Tumor growth assessment: Data for each 
time-point in mm3 are mean ± SEM. A) Day 28: Control vs Cy and vs Cy+Dox (P<0.05); 
Day 31: Cy vs Dox and vs Cy+Dox (P<0.05); B) Day 31: Control vs Cy; Dox vs Cy+Dox 
(P<0.05) One way ANOVA/Tukey. Day 5: Cy vs Cy+Dox (P<0.05) t Test. Overall 
survival: C) (P<0.05); D) (P<0.01), Log-rank Test. 
Figure 2: Antimetastatic effect: Number of lung metastatic foci (median, range): A) 
Control vs Cy+Dox (P<0.05), vs Cy (P<0.001); B) Control vs Cy+Dox (P<0.05), Kruskal-
Wallis/Dunn´s. Metastases diameter (mm; mean ± SEM): C) Cy+Dox vs Control 
(P<0.001) vs Cy and Dox (P<0.01); D) NS, One way Anova/Tukey. Total metastatic 
burden (mm3; mean ± SEM): E) Control vs Cy and Cy+Dox (P<0.001) and vs Dox 
(P<0.05), Dox vs Cy+Dox (P<0.01); F) Control vs Cy and Dox (P<0.01), vs Cy+Dox 
(P<0.001), One way Anova/Tukey. Overall survival: G) P<0.0001; H: P<0.0001; Log-rank 
Test.  
Figure 3: VEGF serum concentration: blood samples were taken on day 0 and on days 24 
and 25 from mice bearing M-234p (A) and M-406 (B) tumors, respectively. Data for each 
time-point are mean ± SEM serum concentration. A) Control vs Day 0, vs Dox, vs Cy and 
vs Cy+Dox (P<0.001); B) Control vs Day 0 (P<0.01) vs Dox and vs Cy+Dox (P<0.05), 
ANOVA/Tukey.  
Figure 4: Ki-67 expression. The score (median, range) of Ki67+ cells and sections of M-
234p (A) and M-406 (B) tumors (X100 magnification), obtained on days 31 and 26, 
respectively, is shown. A) Control vs Cy+Dox (P<0.05), B) NS, Kruskal–Wallis /Dunn’s. 
Apoptosis. The number of TUNEL+ cells/field (median, range) and sections of M-234p (C) 
and M-406 (D) tumors (X100 magnification), obtained on days 31 and 26, respectively. is 
shown. C) NS, D) Control vs Cy+Dox (P<0.05), Kruskal–Wallis/Dunn’s.  
Supplementary Material 1. Evolution of body weight: data for each time-point are the 
percentage of initial body weight (mean ± SEM): A) M-234-p; B) M-406. No significant 
body weight losses were detected in either tumor-model, during treatment. Total leukocytes 
count, C) Day 0 vs Control and vs Dox (P< 0.01), D) Day 0 vs Control (P<0.01), vs Dox 
(P<0.05), Kruskal–Wallis/Dunn’s.  
Supplementary Material 2. Tumor microvascular density (MVD) and area (MVA). NS, 
Kruskal–Wallis /Dunn’s. 
Supplementary Material 3. T regulatory cells. Percentage of circulating 
CD4+CD25+Foxp3+ Treg cells (median, range). A) NS, B) Kruskal Wallis Test (P<0.01), 
Dunn’s Multiple Comparison Test, NS. 
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Supplementary material 2 
 
 
Experimental 
Groups 
M-234p 
 
M-406 
MDa 
 
MAb MDa MAb 
 
Control 
 
19 
(17-35) 
19 
(8.3-35.2) 
21 
(16-26) 
31 
(19.2-47.5) 
 
Cy + Dox 
 
17 
(13-20) 
11 
(9.4-14.4) 
19 
(18-20) 
18 
(10.9-29.5) 
a N° of CD31+ vessels/field (400X); median (range) 
b % of tissue occupied by vessels/field (400X); median (range) 
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